Literature DB >> 6982087

Impaired T-cell and NK-cell function in patients with preleukemia.

F Porzsolt, H Heimpel.   

Abstract

The responses to the T-cell mitogens Phythemagglutinin (PHA) and Concanavalin A (Con A) and the natural killer (NK) cell activity are tested in patients with preleukemia (PL). The results are compared with those of healthy controls. The PL patients show low responses to T-cell mitogens and low NK cell activities. It is discussed that the data are not of prognostic value in PL as to development of overt leukemia. However, the results suggest that PL impaired cell functions are not limited to erythropoiesis, granulopoiesis, and thrombopoiesis but are also found in the immune system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982087     DOI: 10.1007/BF00320191

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  30 in total

1.  K562--a human erythroleukemic cell line.

Authors:  L C Andersson; K Nilsson; C G Gahmberg
Journal:  Int J Cancer       Date:  1979-02       Impact factor: 7.396

2.  Preleukemic states.

Authors:  R V Pierre
Journal:  Semin Hematol       Date:  1974-01       Impact factor: 3.851

3.  [Functional disorders of the hematopoietic system in the preleukemic phase of acute undifferentiated leukemia].

Authors:  H Heimpel; E Kleihauer; A Olischläger; W Queisser
Journal:  Med Klin       Date:  1972-08-04

4.  Preleukemic leukemia. A report of four cases.

Authors:  H Salomon; I Tatarsky
Journal:  Isr J Med Sci       Date:  1969 Nov-Dec

5.  Some studies on natural killer cells in man.

Authors:  E Lotzová; K B McCredie; J A Maroun; K A Dicke; E J Freireich
Journal:  Transplant Proc       Date:  1979-06       Impact factor: 1.066

6.  [Effector function of acute leukemias in "spontaneous" (SCMC) and antibody dependent cellular cytotoxicity-tests (ADCC) (author's transl)].

Authors:  P Schmidt; H H Peter; J R Kalden; H J Avenarius; H Bodenstein
Journal:  Klin Wochenschr       Date:  1978-10-01

7.  Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow (smoldering acute leukemia).

Authors:  B Dreyfus
Journal:  Nouv Rev Fr Hematol Blood Cells       Date:  1976

Review 8.  The preleukemic syndrome (hemopoietic dysplasia).

Authors:  J W Linman; G C Bagby
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

9.  Polyploidization of megakaryocytes in normal humans, in patients with idiopathic thrombocytopenia and with pernicious anaemia.

Authors:  U Queisser; W Queisser; B Spiertz
Journal:  Br J Haematol       Date:  1971-05       Impact factor: 6.998

10.  Platelet function in preleukaemia.

Authors:  R Lintula; V Rasi; E Ikkala; G H Borgström; P Vuopio
Journal:  Scand J Haematol       Date:  1981-01
View more
  6 in total

1.  Coincidence of primary myelodysplastic syndrome and non-Hodgkin lymphoma.

Authors:  R Schulze; G Schlimok; D Renner
Journal:  Clin Investig       Date:  1992-12

2.  Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.

Authors:  G De Sanctis; V Bottari; A Frezzolini; M Ficcardi; G De Rossi; M C Petti; F Mandelli; L Fontana
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.

Authors:  O Iwase; S Aizawa; Y Kuriyama; M Yaguchi; M Nakano; K Toyama
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

4.  The origin of human NK cells. An ontogenic model derived from studies in patients with immunodeficiencies.

Authors:  H H Peter
Journal:  Blut       Date:  1983-05

5.  Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.

Authors:  Pearlie K Epling-Burnette; Fanqi Bai; Jeffrey S Painter; Dana E Rollison; Helmut R Salih; Matthias Krusch; Jianxiang Zou; Edna Ku; Bin Zhong; David Boulware; Lynn Moscinski; Sheng Wei; Julie Y Djeu; Alan F List
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113

6.  The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome.

Authors:  X Yataganas; G Eliopoulos; S Koulocheri; N Viniou; E Plata; P Panagiotidis; G Vayopoulos; J Meletis; P Fessas
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.